Physician profile
Douglas Stuart
NPI 1548251572
$492,690.83
in general payments reported to CMS, 2019-2025
54 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $24K · 2021: $48K · 2022: $79K · 2023: $83K · 2024: $48K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Consulting Fee: $29K · Food and Beverage: $15K · Travel and Lodging: $8,103 · Education: $16.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,557.50 |
| Consulting Fee | $29,107.63 |
| Food and Beverage | $15,131.44 |
| Travel and Lodging | $8,103.11 |
| Education | $16.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $113,401.63 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Tg Therapeutics, INC. | $107,373.52 | 2023-2025 | Briumvi |
| E.R. Squibb & Sons, L.L.C. | $89,528.29 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $66,259.80 | 2019-2025 | |
| Celgene Corporation | $47,969.86 | 2019-2025 | Zeposia |
| Genentech USA, INC. | $20,604.19 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $16,330.65 | 2019-2025 | Uplizna, Aimovig |
| Emd Serono, INC. | $12,177.90 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $8,243.18 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $3,729.74 | 2021-2023 | Uplizna |
| Abbvie INC. | $1,157.08 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Ucb, INC. | $618.29 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Argenx US, INC. | $476.82 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $454.61 | 2019-2025 | |
| Eisai INC. | $373.30 | 2022-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $344.68 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $341.92 | 2022-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $336.17 | 2020-2025 | Nuplazid |
| Lilly USA, LLC | $300.33 | 2019-2025 | Kisunla, Emgality |
| Pfizer INC. | $216.61 | 2022-2025 | |
| Lundbeck LLC | $184.63 | 2023-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $174.53 | 2020-2025 | Wakix |
| Sk Life Science, INC. | $156.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $149.68 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $125.75 | 2025 | Ponvory |
| Arbor Pharmaceuticals, INC. | $113.51 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $109.44 | 2022-2025 | Ampyra, Inbrija, Xeomin |
| Banner Life Sciences, LLC | $109.35 | 2022-2024 | |
| Neurelis, INC. | $98.96 | 2023-2025 | Valtoco |
| Mdd US Operations, LLC | $91.94 | 2024 | Gocovri |
| Impel Pharmaceuticals INC. | $89.79 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $87.84 | 2023-2025 | Sunosi, Symbravo |
| Boston Scientific Corporation | $82.56 | 2021 | |
| Mallinckrodt Hospital Products INC. | $78.81 | 2023-2024 | Acthar |
| Amneal Pharmaceuticals LLC | $78.51 | 2020-2025 | Crexont, Lyvispah |
| Acorda Therapeutics, INC | $78.27 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $69.92 | 2025 | Dysport |
| Catalyst Pharmaceuticals, INC. | $69.35 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $66.87 | 2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $59.37 | 2023-2025 | Wainua, Flumist Quadrivalent |
| Cycle Pharmaceuticals INC | $43.17 | 2024-2025 | Tascenso Odt |
| Livanova USA, INC. | $43.05 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Idorsia Pharmaceuticals US INC | $37.19 | 2023 | Quviviq |
| Impel Pharmaceuticals LLC | $36.67 | 2024-2025 | Trudhesa |
| Kyowa Kirin, INC. | $27.99 | 2022-2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $27.63 | 2024 | Amvuttra |
| Invivyd INC | $27.19 | 2025 | Pemgarda |
| Sanofi-Aventis U.S. LLC | $24.36 | 2020 | |
| Janssen Biotech, INC. | $20.42 | 2025 | |
| Immedica Pharma US, INC. | $20.18 | 2023 | |
| Jazz Pharmaceuticals INC. | $20.04 | 2022 | |
| Octapharma USA, INC. | $18.49 | 2025 | Panzyga |
| Tanabe Pharma America, INC. | $15.70 | 2025 | Radicava |
| Greenwich Biosciences, INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.